Brief: Femasys Enrollment Over 25% Complete For Femaseed De Novo Trial
29/11/2022 12:30
Nov 29 (Reuters) - Femasys Inc FEMY.O :
* FEMASYS INC. ANNOUNCES ENROLLMENT IS OVER 25% COMPLETE FOR
FEMASEED® DE NOVO TRIAL FOLLOWING UPDATED STRATEGIC STUDY DESIGN
Source text for Eikon: ID:nGNX6PbpNJ
Further company coverage: FEMY.O
((Reuters.Briefs@thomsonreuters.com;))